Operational standard for the clinical use of Lecanemab in Alzheimer’s Disease

Abstract

Background: Lecanemab is approved by FDA for early Alzheimer’s disease (AD) treatment, and has entered China by the end of June 2024. However, adverse events may occur with Lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions.